Sangamo Therapeutics announced the conclusion of a court-supervised Section 363 auction under its Chapter 11 bankruptcy case, selecting winning bids from PTC Therapeutics and Eli Lilly. The transactions yield approximately $163.55 million in cash consideration at closing plus potential milestone payments up to $100 million. PTC will acquire the Fabry disease program isaralgagene civaparvovec for $111 million upfront and up to $100 million in milestones, while Lilly will purchase capsid delivery, zinc finger, MINT platforms, and a prion disease program for $50 million. Additional assets including tools and equipment were sold for $2.55 million. The sales remain subject to Bankruptcy Court approval and Hart-Scott-Rodino clearance, with expected closings in September 2026 or later. Sangamo Therapeutics is a genomic medicine company developing therapies for rare diseases.
